Health

Survival Benefit Continues at 10 Years From Opdivo Either Alone or With Yervoy in Advanced Melanoma

Among patients with advanced melanoma, treatment with Opdivo (nivolumab) with or without Yervoy (ipilimumab) benefited both overall survival (OS, the time a patient lives, regardless of disease status) and melanoma-specific survival (MSS, the time until a patient with melanoma dies

Survival Benefit Continues at 10 Years From Opdivo Either Alone or With Yervoy in Advanced Melanoma Read More »